Steven M Horwitz

28PUBLICATIONS
227CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Jun 29, 2026
Extranodal natural killer/T-cell lymphoma: From fatal to curable.

|Apr 29, 2026
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.

|Apr 22, 2026
Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

|Oct 28, 2025
Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma.

Masaya Tachibana, Steven Horwitz, Eric Jacobsen

|Aug 01, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Eva Domingo-Domènech, Barbara Pro, Tim Illidge

|Feb 08, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye

Pageof 5

Frequent Collaborators

7 joint publications

Maria Lia Palomba

7 joint publications

Gilles Salles

7 joint publications

Andrew D Zelenetz

6 joint publications

Ahmet Dogan